Richard Tothill is a senior post-doctoral scientist within the Cancer Therapeutics Program at the Peter MacCallum Cancer Centre (Peter Mac). His research interests encompass the use of genomic technologies to understand the genetic basis of cancer, which extends to cancer cell biology, transcription and epigenetics. His past highly cited work has involved the use gene-expression profiling for the molecular classification of solid tumours such as ovarian cancer and cancers of unknown primary. In recent times his focus has shifted to neuroendocrine cancers encompassing rare cancer types such as phaeochromocytoma and Merkel cell carcinoma as well as haematological malignancies with an emphasis on understanding tumour heterogeneity and cancer evolution. He is also involved with the clinical translation of genomic technologies at the Peter Mac with an active role in the co-development of clinical sequencing methods for the deployment of personalised genomic medicine.
Abstracts this author is presenting: